Targeted Therapies in Oncology
December II, 2024
Volume: 13
Issue: 16
December I, 2024
Volume: 13
Issue: 15
November I, 2024
Volume: 13
Issue: 14
October I, 2024
Volume: 13
Issue: 13
September II, 2024
Volume: 13
Issue: 12
September I, 2024
Volume: 13
Issue: 11
August I, 2024
Volume: 13
Issue: 10
July I, 2024
Volume: 13
Issue: 9
June 02, 2024
Volume: 13
Issue: 8
June I, 2024
Volume: 13
Issue: 7
May I, 2024
Volume: 13
Issue: 6
April I, 2024
Volume: 13
Issue: 5
March II, 2024
Volume: 13
Issue: 4
March I, 2024
Volume: 13
Issue: 3
February I, 2024
Volume: 13
Issue: 2
January I, 2024
Volume: 13
Issue: 1
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Pelareorep Offers Promise in Second-Line KRAS-Mutant Metastatic CRC
4
Phase 3 Data Highlight Orca-T’s Clinical Benefits in Heme Malignancies
5